ServiceUpdated on 1 September 2025
In Silico Solutions to De-risk Drug Development and Empower Precision Medicine
About
Our service can:
- Help de-risk development pipelines by assessing the impact of novel mutations (e.g., kinase activation), supporting patient selection for targeted therapies and reducing unsuccessful treatments;
- Evaluate drug efficacy by analyzing both simple and complex mutations;
- Assist with cohort selection by refining patient inclusion criteria for clinical trials, increasing trial success rates.
Our services are ideally suited for advanced targeted therapies, with current expertise focused on tyrosine kinase inhibitors (TKIs).
Type
- Development
- Consulting
Applies to
- Innovative therapies - Precision medicine
- Innovative human-based test models - In silico human models
- Development stages and support fuctions - Pre-clinical research and development
- Development stages and support fuctions - Clinical research and development
- Development stages and support fuctions - Contract research (CRO / CRMO)
Organisation
Similar opportunities
Partnership
Partnership opportunities in advanced targeted therapies for cancer
Rositsa Jordanova
CEO and founder at Protyon
Groningen, Netherlands
Project cooperation
Precision oncology for advanced targeted therapies
- Early
- Research
- Financing
Rositsa Jordanova
CEO and founder at Protyon
Groningen, Netherlands
Service
Real-Time Risk and Triage Analytics
- Development stages and support fuctions - Regulatory and compliance
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Development stages and support fuctions - Ethics and social responsibility
- Development stages and support fuctions - Commercial strategy and market access
Johannes Wubbe
President of the board at DocSWISS
Zürich, Switzerland